SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

21 Jan 2025 Evaluate
Net sales declined -16.94%  to  Rs. 3729.80 million from Rs. 4490.50 millions.The Net Loss for the quarter ended December 2024 is Rs. -102.30 millions as compared to Net Profit of Rs. 200.10 millions of corresponding quarter ended December 2023A decline of 244.00 millions was observed in the OP in the quarter ended December 2024 from 682.20 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 3729.80 4490.50 -16.94 11709.40 13453.20 -12.96 17908.10 16666.90 7.45
Other Income 42.60 29.30 45.39 119.80 44.60 168.61 85.10 23.30 265.24
PBIDT 244.00 682.20 -64.23 1365.60 2050.80 -33.41 2664.90 2872.20 -7.22
Interest 140.00 100.30 39.58 406.50 259.10 56.89 368.20 250.30 47.10
PBDT 113.90 499.90 -77.22 969.00 1709.70 -43.32 2412.00 2621.90 -8.01
Depreciation 247.50 229.70 7.75 733.70 642.50 14.19 879.80 706.00 24.62
PBT -133.60 270.20 -149.44 235.30 1067.20 -77.95 1532.20 1915.90 -20.03
TAX -31.30 70.10 -144.65 60.20 276.30 -78.21 365.80 502.30 -27.17
Deferred Tax 19.10 47.70 -59.96 30.90 53.30 -42.03 38.10 -49.70 -176.66
PAT -102.30 200.10 -151.12 175.10 790.90 -77.86 1166.40 1413.60 -17.49
Equity 184.40 184.30 0.05 184.40 184.30 0.05 184.40 184.30 0.05
PBIDTM(%) 6.54 15.19 -56.94 11.66 15.24 -23.50 14.88 17.23 -13.65

Indoco Remedies Share Price

206.85 -7.20 (-3.36%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×